Organization | European Clinical Research Infrastructure Network

European Clinical Research Infrastructure Network Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2016

NCT02599480

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN) | European Clinical Research Infrastructure Network

Active Ingredients

Drugs in Phase 3 Trials (1)

allogeneic bone marrow derived mesenchymal stem cell (1 trial)

Drugs in Phase 2 Trials (4)

allogeneic adipose derived mesenchymal stem cell (1 trial)

echitabplus-icp (1 trial)

fludeoxyglucose f-18 (1 trial)

mirabegron (myrbetriq) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Back Pain (Phase 3)

Hypertrophy (Phase 2)

Hypertrophy, Left Ventricular (Phase 2)

Intervertebral Disc Degeneration (Phase 3)

Low Back Pain (Phase 3)

Osteoarthritis (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial APIs: 5